Related Experiment Video
Updated: Jun 23, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells
Isabel Tritschler1, Dorothee Gramatzki, David Capper
1Department of General Neurology, Laboratory of Molecular Neuro-Oncology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Abstract:
High biological activity of the transforming growth factor (TGF)-beta-Smad pathway characterizes the malignant phenotype of malignant gliomas and confers poor prognosis to glioma patients. Accordingly, TGF-beta has become a novel target for the experimental treatment of these tumors. TGF-beta is processed by furin-like proteases (FLP) and secreted from cells in a latent complex with its processed propeptide, the latency-associated peptide (LAP). Latent TGF-beta-binding protein 1 (LTBP-1) covalently binds to this small latent TGF-beta complex (SLC) and regulates its function, presumably via interaction with the extracellular matrix (ECM). We report here that the levels of LTBP-1 protein in vivo increase with the grade of malignancy in gliomas. LTBP-1 is associated with the ECM as well as secreted into the medium in cultured malignant glioma cells. The release of LTBP-1 into the medium is decreased by the inhibition of FLP activity. Gene-transfer mediated overexpression of LTBP-1 in glioma cell lines results in an increase inTGF-beta activity. Accordingly, Smad2 phosphorylation as an intracellular marker of TGF-beta activity is enhanced. Conversely, LTBP-1 gene silencing reduces TGF-beta activity and Smad2 phosphorylation without affecting TGF-beta protein levels. Collectively, we identify LTBP-1 as an important modulator of TGF-beta activation in glioma cells, which may contribute to the malignant phenotype of these tumors.
Insights
Latent TGF-beta-binding protein 1 (LTBP-1) levels correlate with glioma malignancy. LTBP-1 enhances transforming growth factor-beta (TGF-beta) activity, suggesting it as a therapeutic target for malignant gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- The transforming growth factor-beta (TGF)-beta-Smad pathway is crucial in malignant gliomas, impacting patient prognosis.
- TGF-beta is a therapeutic target, but its activation mechanism in gliomas requires further elucidation.
- Latent TGF-beta-binding protein 1 (LTBP-1) binds to latent TGF-beta complexes and may influence extracellular matrix interactions.
Purpose of the Study:
- To investigate the role of LTBP-1 in modulating TGF-beta activity in malignant gliomas.
- To determine the relationship between LTBP-1 levels and glioma grade.
- To explore LTBP-1 as a potential therapeutic target in glioma treatment.
Main Methods:
- Quantification of LTBP-1 protein levels in gliomas of varying malignancy grades.
- Analysis of LTBP-1 localization in glioma cells and extracellular matrix (ECM).
- Investigation of LTBP-1's effect on TGF-beta activity using gene overexpression and silencing techniques, and measurement of Smad2 phosphorylation.
Main Results:
- LTBP-1 protein levels increase with glioma malignancy grade.
- LTBP-1 is found in the ECM and secreted by glioma cells, with release dependent on furin-like protease (FLP) activity.
- Overexpression of LTBP-1 enhances TGF-beta activity and Smad2 phosphorylation, while LTBP-1 gene silencing reduces them.
Conclusions:
- LTBP-1 is identified as a significant modulator of TGF-beta activation in glioma cells.
- LTBP-1 contributes to the malignant phenotype of gliomas.
- LTBP-1 represents a potential therapeutic target for managing malignant gliomas.
Related Concept Videos
01:16TGF - β Signaling Pathway
02:23Abnormal Proliferation